CA2546853C - Use of interfering rna in the production of transgenic animals - Google Patents

Use of interfering rna in the production of transgenic animals Download PDF

Info

Publication number
CA2546853C
CA2546853C CA2546853A CA2546853A CA2546853C CA 2546853 C CA2546853 C CA 2546853C CA 2546853 A CA2546853 A CA 2546853A CA 2546853 A CA2546853 A CA 2546853A CA 2546853 C CA2546853 C CA 2546853C
Authority
CA
Canada
Prior art keywords
gene
cell
cells
sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2546853A
Other languages
English (en)
French (fr)
Other versions
CA2546853A1 (en
Inventor
Kevin Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revivicor Inc
Original Assignee
Revivicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revivicor Inc filed Critical Revivicor Inc
Publication of CA2546853A1 publication Critical patent/CA2546853A1/en
Application granted granted Critical
Publication of CA2546853C publication Critical patent/CA2546853C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2546853A 2003-11-21 2004-11-22 Use of interfering rna in the production of transgenic animals Expired - Lifetime CA2546853C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52393803P 2003-11-21 2003-11-21
US60/523,938 2003-11-21
PCT/US2004/039191 WO2005081714A2 (en) 2003-11-21 2004-11-22 Use of interfering rna in the production of transgenic animals

Publications (2)

Publication Number Publication Date
CA2546853A1 CA2546853A1 (en) 2005-09-09
CA2546853C true CA2546853C (en) 2020-04-21

Family

ID=34910676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546853A Expired - Lifetime CA2546853C (en) 2003-11-21 2004-11-22 Use of interfering rna in the production of transgenic animals

Country Status (7)

Country Link
US (1) US10793873B2 (https=)
EP (2) EP1734811A4 (https=)
JP (1) JP2007512027A (https=)
CN (2) CN1972593A (https=)
AU (1) AU2004316293A1 (https=)
CA (1) CA2546853C (https=)
WO (1) WO2005081714A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439438T1 (de) * 2003-05-23 2009-08-15 Sirna Therapeutics Inc Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von chemisch modifizierter sina (short interfering nucleic acid)
WO2005009134A1 (en) 2003-07-21 2005-02-03 Lifecell Corporation ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE
EP1582591A3 (en) * 2004-02-27 2005-12-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Sirna and their use for knock down expression of porcine endogenous retrovirus
RU2008102646A (ru) * 2005-06-24 2009-07-27 Риджентс Оф Дзе Юниверсити Оф Миннесота (Us) Применение цитозиндезаминаз для уменьшения переноса ретроэлементов от свиней человеку
JP2007104969A (ja) * 2005-10-13 2007-04-26 Bio Think Tank Co Ltd ショートヘアピン型ＲＮＡ（ｓｈＲＮＡ）前駆体を産生するための核酸及びその利用
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
US8258286B2 (en) 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
JP5554231B2 (ja) * 2007-06-13 2014-07-23 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション トリの生産形質の改変
US8309791B2 (en) * 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
EP2425015B1 (en) * 2009-04-29 2018-01-10 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
ES2875764T3 (es) 2009-08-14 2021-11-11 Univ California Métodos para diagnosticar y tratar autismo
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US20130139273A1 (en) * 2010-06-24 2013-05-30 The Ohio State University Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression
ES2739804T3 (es) 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
US9693555B2 (en) * 2011-03-18 2017-07-04 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Insect-combating preparation and method based on RNAi technology
US9980471B2 (en) * 2012-06-12 2018-05-29 The General Hospital Corporation Miniature swine transgenic for one or more coagulation factors
EP3065790B1 (en) 2013-11-04 2020-10-28 LifeCell Corporation Methods of removing alpha-galactose
CN104677866A (zh) * 2014-03-25 2015-06-03 中国科学院大连化学物理研究所 测定CP装载siRNA体系中siRNA释放的方法
JP6663859B2 (ja) 2014-05-20 2020-03-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション ハンチントン病の治療化合物
CN104232670A (zh) * 2014-08-25 2014-12-24 中国水产科学研究院黑龙江水产研究所 一种采用鱼类转基因方法构建的基于鲤鱼mstn干涉载体及其构建方法
JP6873060B2 (ja) 2015-06-26 2021-05-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 自閉症を診断および治療するための抗原性ペプチドおよびその使用
EP4491732A3 (en) * 2015-10-08 2025-03-26 President and Fellows of Harvard College Multiplexed genome editing
CN106918697B (zh) * 2017-02-15 2018-07-31 中国医学科学院北京协和医院 一种预测ra药物疗效的诊断标志物及其应用
WO2018195402A1 (en) * 2017-04-20 2018-10-25 Egenesis, Inc. Methods for generating genetically modified animals
CN107760682B (zh) * 2017-10-18 2020-12-18 云南大学 一种可用于分子防治害虫的核酸序列及其应用
CN110628807B (zh) * 2018-05-30 2021-06-18 中国科学院植物研究所 盐角草SePSS蛋白及其编码基因与应用
WO2020033456A1 (en) * 2018-08-06 2020-02-13 Nemametrix Inc Homologous recombination reporter construct and uses thereof
KR20210089659A (ko) 2018-10-05 2021-07-16 제노세라퓨틱스, 인코포레이티드 이종이식 생성물 및 방법
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
EP3877530A1 (en) * 2018-11-08 2021-09-15 Greenlight Biosciences, Inc. Control of insect infestation
CN110055253A (zh) * 2019-04-28 2019-07-26 复旦大学附属金山医院 一种针对人半胱氨酸蛋白酶抑制剂B的siRNA分子及其应用
US20220012673A1 (en) * 2020-07-13 2022-01-13 ZenDesk, Inc. Maintaining status information for customer-support agents across multiple channels
KR20230117147A (ko) * 2020-12-01 2023-08-07 에테하 쭈리히 대안적 프로모터를 포함하는 dna 작제물
CA3217458A1 (en) * 2021-05-06 2022-11-10 Spyro Mousses Sirna constructs for inhibiting gene expression in targeted cancer cells
WO2022256294A1 (en) * 2021-06-01 2022-12-08 University Of Massachusetts Cas9 nickase-mediated gene editing
WO2023004365A1 (en) * 2021-07-20 2023-01-26 Sio Gene Therapies Inc. Vector constructs for delivery of nucleic acids encoding therapeutic proteasome activator complex subunits and methods of using the same
CN115011601B (zh) * 2022-06-27 2023-07-21 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用
CN118581151B (zh) * 2024-05-29 2024-12-06 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种猪becn1基因敲除细胞的构建方法及其应用
CN120608104B (zh) * 2025-08-12 2025-11-25 中国科学院水生生物研究所 lasp1基因在鱼类抗病毒免疫调控中的功能和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4517338A (en) 1983-06-20 1985-05-14 Chiron Corporation Multiple reactor system and method for polynucleotide synthesis
US4888274A (en) 1985-09-18 1989-12-19 Yale University RecA nucleoprotein filament and methods
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2323069A1 (en) 1998-03-12 1999-09-16 Taisho Pharmaceutical Co., Ltd. Nucleic acid enzyme showing allosteric rna-cleaving activity on target rna
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
US6261806B1 (en) 1998-08-18 2001-07-17 Biotransplant, Inc. Molecular sequence of swine retrovirus and methods of use
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20030143597A1 (en) * 2000-12-28 2003-07-31 Finney Robert E. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
JPWO2002092821A1 (ja) 2001-05-01 2004-09-02 独立行政法人産業技術総合研究所 新規マキシザイム
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
AU2002329667A1 (en) 2001-07-30 2003-02-17 Uta Griesenbach Specific inhibition of gene expression by small double stranded rnas
AU2002326906C1 (en) * 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
AU2002353231B2 (en) 2001-12-21 2008-10-16 Oxford Biomedica (Uk) Limited Method for producing a transgenic organism using a lentiviral expression vector such as EIAV
WO2003059923A2 (en) 2001-12-21 2003-07-24 Tranzyme, Inc. Methods and compositions for generating a genetically modified animal using lentiviral vectors
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
DK1534819T3 (da) 2002-08-21 2010-04-19 Revivicor Inc Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase
US20040072769A1 (en) * 2002-09-16 2004-04-15 Yin James Qinwei Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs
CN1276976C (zh) * 2003-10-30 2006-09-27 封江南 单一载体编码多个发夹结构小干扰性rna表达系统及其构建方法
EP1582591A3 (en) * 2004-02-27 2005-12-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Sirna and their use for knock down expression of porcine endogenous retrovirus

Also Published As

Publication number Publication date
EP1734811A2 (en) 2006-12-27
CN103397019A (zh) 2013-11-20
WO2005081714A2 (en) 2005-09-09
EP1734811A4 (en) 2009-03-25
JP2007512027A (ja) 2007-05-17
EP2514826A2 (en) 2012-10-24
US10793873B2 (en) 2020-10-06
EP2514826A3 (en) 2013-04-03
CN1972593A (zh) 2007-05-30
AU2004316293A1 (en) 2005-09-09
WO2005081714A3 (en) 2006-11-16
CA2546853A1 (en) 2005-09-09
US20050266561A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
CA2546853C (en) Use of interfering rna in the production of transgenic animals
US12213466B2 (en) Process for using CRISPR to transfect primordial germ cells in avians
US10300112B2 (en) Transgenic ungulates expressing CTLA4-IG and uses thereof
Oberdoerffer et al. Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages
US7368284B2 (en) Porcine CMP-N-Acetylneuraminic acid hydroxylase gene
JP2022113700A (ja) ＣＲＩＳＰＲ－Ｃａｓゲノム編集に基づく、Ｆｅｌ ｄ１ノックアウト並びに関連組成物及び方法
JP2010526542A (ja) インフルエンザの治療および予防
WO2018030536A1 (ja) ゲノム編集方法
EP2201116B1 (en) Means and methods for shrna mediated conditional knockdown of genes
AU2015204349B2 (en) Use of interfering RNA in the production of transgenic animals
CN118389520B (zh) 小鼠进行基因敲除的方法及构建的ghr基因敲除小鼠模型
Baup et al. Variegation and silencing in a lentiviral-based murine transgenic model
NZ547388A (en) Use of interfering RNA in the production of transgenic animals
AU2012205138A1 (en) Use of interfering RNA in the production of transgenic animals
US20250051759A1 (en) METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
DA et al. interference.
HK1178572A (en) Treatment and prevention of influenza

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250522